Xeris Biopharma Holdings (XERS) Inventory Average (2021 - 2026)

Xeris Biopharma Holdings has reported Inventory Average for 6 years, with the latest figure at $71.5 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 41.68% year-over-year to $71.5 million; the trailing twelve-month figure through Mar 2026 stood at $71.5 million (up 41.68% YoY), and the FY2025 full-year result was $58.4 million, up 34.29% from the prior year.
• Inventory Average for Q1 2026 stood at $71.5 million, up from $68.1 million in the prior quarter.
• The five-year high for Inventory Average was $71.5 million in Q1 2026, with the low at $17.4 million in Q2 2022.
• Historically, Inventory Average has averaged $41.3 million across 5 years, with a median of $39.9 million in 2024.
• Annual changes were most pronounced in 2023 — Inventory Average jumped 96.49% — and 2024, when it grew 17.96%.
• Xeris Biopharma Holdings' Inventory Average stood at $22.4 million in 2022, then jumped by 71.62% to $38.5 million in 2023, then climbed by 21.19% to $46.6 million in 2024, then surged by 45.92% to $68.1 million in 2025, then increased by 4.97% to $71.5 million in 2026.
• The last three Inventory Average figures came in at $71.5 million (Q1 2026), $68.1 million (Q4 2025), and $67.4 million (Q3 2025), per Business Quant data.